Zachary Klaassen interviews Pratik Kanabur about a presentation on the cost-effectiveness of zirconium-girentuximab PET imaging for small renal masses. Dr. Kanabur explains that current diagnostic ...

Weranja Ranasinghe discusses research on developing an immunohistochemistry (IHC) profile to predict response to BCG in non-muscle invasive bladder cancer (NMIBC). In this pilot study analyzing ...

Endoscopic enucleation of the prostate (EEP) has become a gold standard for the surgical treatment of symptomatic benign prostatic hyperplasia (BPH). Thulium fiber laser enucleation (ThuFLEP), due to ...

Oxidative stress contributes to benign prostatic hyperplasia (BPH) pathogenesis, but its role in BPH with bladder diverticulum is unclear. This prospective cohort study compared 126 BPH patients at ...

Tranexamic acid (TXA) is an anti-fibrinolytic agent that prevents degradation of fibrin by blocking the ability of plasminogen to bind to fibrin and the proteolytic activity of plasmin. TXA has been ...

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a bladder disorder with no definite aetiology and currently no effective treatment. Its clinical symptoms vary widely, and the bladder condition ...

Benign prostatic hyperplasia (BPH) is a common condition that affects elderly men, but its relationship with central obesity in the American population has not been adequately elucidated. In this ...

There is a high number of acute renal colic cases that present to the emergency department, and it is crucial to have reliable parameters that can accurately predict the likelihood of spontaneous ...

Advanced or metastatic urothelial carcinoma (UC) is an incurable disease with a high disease burden and a poor prognosis. Avelumab as first-line (1L) maintenance treatment is an innovative therapy ...